Skip to main content

Published locations for HER2+ BC: Recurrence risk remains even after achieving pCR with neoadjuvant pertuzumab+trastuzumab

Primary tabs

  • View
  • Get Stamp Tags
  • Published Locations

Breadcrumb

  1. Home
  3. HER2+ BC: Recurrence risk remains even after achieving pCR with neoadjuvant pertuzumab+trastuzumab

User login

  • Reset your password
  • /content/her2-bc-recurrence-risk-remains-even-after-achieving-pcr-neoadjuvant-pertuzumabtrastuzumab
  • /hematology-oncology/article/238160/breast-cancer/her2-bc-recurrence-risk-remains-even-after
  • /breast-cancer-icymi/article/238160/breast-cancer/her2-bc-recurrence-risk-remains-even-after